Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ironwood’s Next Steps For Linzess: DTC and Traditional Lifecycle Management

This article was originally published in The Pink Sheet Daily

Executive Summary

At its first investor day, Ironwood offered Wall Street details about the ongoing launch of Linzess, one of the few new primary care drugs to hit the market in recent years, laying out plans for what it insists will be a precision-based, cost-effective DTC campaign and a traditional lifecycle management program for the drug.

You may also be interested in...



Ironwood/Forest Hoping To Change The Conversation About Constipation

The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.

Ironwood/Forest Hoping To Change The Conversation About Constipation

The partners began a DTC campaign to promote their constipation drug and ease the conversation between physicians and patients about the often embarrassing condition.

Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest

Both Ironwood and its specialty pharma partner Forest Laboratories are tying their future to the gastrointestinal drug, which has been gaining traction during its first six months on the market, despite the tough environment for primary care drugs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel